


2.15.01



03-07-2001



101628675

To the Honorable Commissioner of Patents and Trademarks:
Please record the attached original documents or copy thereof

1. Name of conveying party(ies)

SynPhar Laboratories, Inc.

Additional name(s) of conveying party(ies) attached?

Yes No

2. Name and address of receiving party(ies):

Name: NAEJA Pharmaceutical Inc.

Address: #2, 4290-91a Street
Edmonton, Alberta, Canada T6E 5V

Additional name(s) & address(es) attached?

Yes No

3. Nature of conveyance:

Assignment Merger
 Security Agreement Change of Name
 Other
Execution Date: 8/12/99

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)
08/513,802

B. Patent No.(s)
5,264,430 5,686,441
5,446,037 5,439,904
5,342,846 5,652,234
5,561,126 5,464,616

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Arent Fox Kintner Plotkin & Kahn PLLC
Street Address: 1050 Connecticut Avenue, N.W., Suite 600
Washington, D.C. 20036-5339

6. Total number of applications and patents involved:

nine (9)

7. Total fee (37 CFR 3.41)..... \$ 360.00

Enclosed-Check No.:
 Authorized to be charged to deposit account

8. Deposit account number: 01-2300
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Robert B. Murray
Name of Person Signing
Reg. No. 22,980

Robert B. Murray February 15, 2001
Signature Date

Total number of pages including cover sheet, attachments, and document: 7

ASSIGNMENT

WHEREAS SynPhar Laboratories Inc., hereinafter (Assignor) a company having its principal office and place of business at Edmonton, Alberta owns at least a part interest in a number of patents and patent applications as reflected in the lists entitled Schedule G attached hereto; and

WHEREAS NAEJA Pharmaceutical Inc., hereinafter (Assignee), a corporation of Alberta having its principal office and place of business at Edmonton, Alberta, is desirous of acquiring an interest therein.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above said Assignor by these presents does sell, assign and transfer unto the said Assignee, its successors, assigns and legal representatives, all of Assignor's right, title and interest in and to the patents and patent applications described in the attached Schedule G.


Witness:



Donald R.M. Bell
Barrister & Solicitor

2800 - 666 Burrard Street
Vancouver, B.C. V6C 2Z7

SynPhar Laboratories Inc.

By: 

Kosuke Harima
Authorized Signatory

The above assignment is hereby accepted by NAEJA Pharmaceutical Inc.


Witness:



WARREN T. BROWN
BARRISTER & SOLICITOR

FIELD ATKINSON FERRATON
2000, 10236 - 101 STREET
EDMONTON, AB T5J 3G1

NAEJA Pharmaceutical Inc.

By: 

Christopher G. Macetich
Authorized Signatory

SCHEDULE G

SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status
Novel 2-Spirocyclopropyl Cephalosporin Sulfone Derivatives & Processes for the Preparation Thereof	SynPhar	014-02	US 07/685,960		Issued, 5264490
	SynPhar	014-04	JP 51351790		Pending
	SynPhar	014-06	HUNG P9201349		Granted, 213612
	SynPhar	014-09	HUNG P9302718		Published, T/61769
	SynPhar	014-10	AU 6613150		Pending
	SynPhar	014-11	SA 92/2505		Issued, 92/2506
	SynPhar	014-12	SA 90/7976		Issued, 90/7976
	SynPhar	014-13	NZ 235589		Issued, 235589
	SynPhar	014-14	D 4091697.9	Elastase	Pending
	SynPhar	014-16	NOR P 932596		Abandoned
	SynPhar	014-19	EP 90914668.0		Pending
	SynPhar	014-19-1 *	UK		Pending
	SynPhar	014-19-2 *	GER 690.32857.5		Pending
	SynPhar	014-19-3 *	FR		Pending
	SynPhar	014-19-4 *	SWIT		Pending
	SynPhar	014-19-5 *	BEL, 0494914		Pending
	SynPhar	014-20	CA 92/00146		Pending
	SynPhar	014-21	AU 1561292		Issued, 668504
	SynPhar	014-22	CA 2,107,891		Pending
	SynPhar	014-23	EP 92907976.2		Pending
SynPhar	014-24	KOR 93-703057		Pending	
SynPhar	014-26	JP 60747292		Pending	
2-((Substituted) methylene)cephalosporin Sulfones as Antiinflammatory, Anti- degenerative and Antithrombin Agents	SynPhar	020-02	US 08/165,576	Elastase	Issued, 5446037

SCHEDULE G (P.2)
 SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status		
Novel 7-(Substituted triazolyl pyrrolidin-1-yl)-4- orosquinoiene-3-carboxylic Acid Derivatives - Useful as antibacterial Agents	SynPhar	022-01	US 07913,506	Quinolone	Issued, 5342846		
	SynPhar	022-03	CA 91/00435		Pending		
	SynPhar	022-06	NZ 240983		Issued, 240883		
	SynPhar	022-07	SA 91/9601		Issued, 91/9601		
	SynPhar	022-08	CA 2,089,591		Pending		
	SynPhar	022-10	EP 91920690.0		Pending		
	SynPhar	022-12	JIN 932696		Pending		
	SynPhar	022-13	NOR P 982033		Pending		
	SynPhar	022-14	HUNG P9301648		Pending		
	SynPhar	022-15	SK 93-701694		Allowed		
	SynPhar	022-17	JP 50006494		Pending		
	4-oxa-1-azabicyclo[3,2,0]- heptan-7-one Derivatives as Antitumor Agents	Taiho & SynPhar	023-01		POT/GB93/01436	Oxapenam	Pending
			023-02		KOR 94-704882		Pending
			023-03		CA 2,139,638		Pending
			023-04		JP 50312294		Pending
			023-05		US 667882,490		Issued, 5,561,126
			023-06		HUNG P9600029		Pending
023-07			FIN 950101	Pending			
023-08			AU 679687	Pending			
023-10			NOR 56.0061	Pending			
023-11			EP 93914908.4	Issued, EP 664995B			
023-12			FR 0 654995	Issued, 0654995			
023-13			GER 69305643.6-08	Issued, 69305643.6			
023-14			IT 41506/BE/96	Issued, 41506/BE/96			
023-15			Netherlands	Issued, 0654995			
023-16			Spain 0 654995	Issued, 0654995			
023-17			Switzerland	Issued, 0654995			
023-18			Sweden 0 654995	Issued, 0654995			
023-19			GB 0 654995	Issued, 0654995			

SCHEDULE G (P.S)

SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status
2-Spirocyclopropyl 4-Acylcephems	SynPhar	026-01	CA 92/00145	Elastase	Pending
	SynPhar	026-02	NZ 249277		Pending
	SynPhar	026-03	SA 92/2504		Issued, 92/2504
	SynPhar	026-04	HUNG P8802717		Pending
	SynPhar	026-05	JP 50747192		Pending
	SynPhar	026-06	AU 1555092		Issued, 688503
	SynPhar	026-07	EP 92507957.2		Granted, 580650
	SynPhar	026-08	CA 2107392		Pending
	SynPhar	026-10	NOR 933595		Pending
	SynPhar	026-11	SK 93708087		Pending
	Oligopeptide Antiretroviral Agents	SynPhar	029-03		US
SynPhar		029-06	CA 2,103,666	Pending	
SynPhar		029-07	SA 92/0964	Issued, SA92/0865	
Cyclopropylpyrrolimide - Oligopeptide Anticancer Agent	SynPhar	029-10	US	Anticancer (Dr. Lown)	Issued, 5502468
	SynPhar	029-13	PCT/US96/00727		Pending
	SynPhar	029-17	SK 705187/1997		Pending
	SynPhar	029-18	AU 49643/96		Issued, 698001
	SynPhar	029-19	EP 95906276.1		Pending
	SynPhar	029-20	JP 528576/96		Pending
	SynPhar	029-21	CA 2,210,083		Pending

SCHEDULE G (P.4)

SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status
2-Spiro(2-Spirocycloalkyl)- cyclopropyl Cephalosporin Sulfones as Antiinflan- matory and Anti- Degenerative Agents	SynPhar SynPhar SynPhar SynPhar SynPhar SynPhar	038-00 038-01 038-02 038-04 038-05 038-06	US 08162,478 CA 94/00669 SA 94/9690 JP 07-515856 EP 95902017.3 CA 2,178,492	Elastase	Issued, 5,439,904 Pending Issued, 94/9690 Pending Pending Pending
Novel 3-(Substituted methyl)-4-oxa-1-azabicyclo- (3,2,0)-heptan-7-ones Derivatives Useful as Antitumor Agents	SynPhar & Taiho	039-00 039-01 039-02 039-03 039-04 039-05 039-06 039-07 039-08	UK 9400220.1 SA 95/0196 PCT/GB95/00024 US 081613,602 SK 95-703785 CA 2,157,502 AU 13250/95 JP 51837595 EP 688324	Oxapenam	Pending Issued, SA 95/0196 Issued Pending Pending Pending Issued, AU 678879 Pending Pending
3-(7-oxo-4-oxabicyclo[3,2,0]- hept-3-yl) Alanine Derivatives as Antitumor Agents	SynPhar & Taiho	043-00 043-01 043-02 043-03 043-04 043-05 043-06 043-07 043-08	UK 9400239.1 SA 95/0107 PCT/GB95/00023 US 081613,903 SK 95-703784 CA 2,157,603 AU 13249/95 JP 51837496 EP 95904657.4	Oxapenam	Pending Issued, SA 95/0107 Pending Issued, US 5652234 Pending Pending Issued, AU 688441 Pending Pending

SCHEDULE G (P.5)

SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status
6β-Substituted Penicillanic Acids as β-Lactamase Inhibitors	SynPhar	045-00	US 06/286,670	Beta-Lactamase	Issued, 5,646,116
	SynPhar	046-01	PCT/IB95/00607		Pending
	SynPhar	046-02	CA 2196480		Pending
	SynPhar	046-03	EP 96925969.8		Pending
	SynPhar	046-04	JP 8-508364/96		Pending
SynPhar	046-05	EP 775144	EP 775144	Pending	
An Improved and Economical Manufacturing Process for 1,2,3-Triazole	SynPhar	047-00	US 06/344,586	Triazole	Issued, 5,527,920
	SynPhar	047-01	INDIA 178909		Pending
	SynPhar	047-02	JP 3000008/96		Pending
A New and Effective Process for the Production of 1,2,3-Triazole	SynPhar	048-00	US 06/282,027	Triazole	Issued, 5,478,947
	SynPhar	048-01	INDIA 357/MAS/95		Pending
Process for Synthesis of Anabessine, Salts Thereof, and Derivatives Thereof and Processes and Intermediate Products	SynPhar	049-00	US 06/301,930	Anabessine	Issued, 5,530,134
	SynPhar	049-01	JP 228945/95		Pending
	SynPhar	049-02	IN 1071/MAS/95		Pending
Nevel Penam Sulfoxes as β-Lactamase Inhibitors	S/T	054-00	US 06/611,227	Beta-Lactamase	Issued, 5,686,441
	SynPhar	054-01	PCT/IB96/00769		Pending
	S/T	054-02	EP 96924103.8		Pending
	S/T	054-03	JP 508267/97		Pending
	S/T	054-04	CA 2,228,528		Pending
Combined Therapy For Treatment Of Inflammation Using Elastase Inhibitor(s) And Antibacterial Agent(s)	SynPhar	070-00	US 60/100,386	Elastase	Pending

* S/T means SynPhar & Taiho

SCHEDULE G (P.6)

SYNPHAR IP RIGHTS

Patent Title	Assignee	Ref. No.	Case Serial #	Project Type	Case Status
Isosquinolones (Class 1)	Warner-Lambert		U.S. 60/029,909	Parke-Davis	Pending
Xenova Compounds	Warner-Lambert		U.S. 60/032,144	Parke-Davis	Pending
Isosquinolones (Class 2, Quinazolinones)	Warner-Lambert		U.S. 60/063,556	Parke-Davis	Pending